Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no request for additional clinical data. Importance Rank: 1 read more

Go to News Site